{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:44:03Z","timestamp":1783651443716,"version":"3.55.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute for Health and Care Research,United Kingdom"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Value-adaptive designs for clinical trials are a novel set of emerging methods for delivering greater value for clinical research. There is increasing interest in using them within publicly funded health systems. A value-adaptive design permits \u2018in progress\u2019 changes to be made to the trial according to criteria which reflect its overall value to the healthcare system, including the cost-effectiveness of the technologies under investigation, the cost of running the trial and the total health benefit delivered to patients. These trial designs offer the potential to explicitly balance the costs and benefits of adaptive clinical trials with the health economic benefits expected for populations that are affected by any subsequent health technology adoption decisions. They may also improve the expected value of learning from the budget that is spent within a trial.\n<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main body<\/jats:title>\n            <jats:p>This paper introduces value-adaptive designs for publicly funded clinical trials. It discusses the idea of delivering \u2018value for money\u2019 in health technology assessment, what is meant by being \u2018value-adaptive\u2019 and the key features that characterise these designs. The methodology behind one kind of value-adaptive design \u2013 the value-based sequential model of a two-armed clinical trial proposed by Chick et al. (2017) \u2013 is described and illustrated using three retrospective case studies from the United Kingdom. The paper concludes by reviewing a range of perspectives provided by stakeholders, together with our own thoughts, on the practical opportunities and changes required for implementing a value-adaptive approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Value-adaptive clinical trial designs offer the potential to align health research funding allocations with population health economic goals. Many of the systems required to deploy value-adaptive designs within a publicly funded health system already exist and, with increased application, experience, and refinement they have the potential to deliver improved value for money.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12874-025-02566-6","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:09:54Z","timestamp":1749107394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Value-adaptive clinical trial designs for efficient delivery of publicly funded trials\u00a0-\u00a0a discussion of methods, case studies, opportunities and challenges"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9569-8290","authenticated-orcid":false,"given":"Laura","family":"Flight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-312X","authenticated-orcid":false,"given":"Alan","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-1571","authenticated-orcid":false,"given":"Stephen E.","family":"Chick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-9062","authenticated-orcid":false,"given":"Martin","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9917-7636","authenticated-orcid":false,"given":"Steven","family":"Julious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9196-0207","authenticated-orcid":false,"given":"Puvan","family":"Tharmanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2566_CR1","doi-asserted-by":"publisher","unstructured":"Pitt C, Goodman C, Hanson K. Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature. Health Econ. 2016 Feb 25;25(S1):9\u201328. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/hec.3305","DOI":"10.1002\/hec.3305"},{"key":"2566_CR2","doi-asserted-by":"crossref","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Heal. 2022;25(1):10\u201331. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521017952","DOI":"10.1016\/j.jval.2021.10.008"},{"issue":"1","key":"2566_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","volume":"16","author":"P Pallmann","year":"2018","unstructured":"Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16(1):29.","journal-title":"BMC Med"},{"issue":"2","key":"2566_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/rssa.12025","volume":"177","author":"P Pertile","year":"2014","unstructured":"Pertile P, Forster M, La TD. Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies. J R Stat Soc Ser A Stat Soc. 2014;177(2):419\u201338.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"6","key":"2566_CR5","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1287\/mnsc.2022.4540","volume":"69","author":"A Alban","year":"2023","unstructured":"Alban A, Chick S, Forster M. Value-based clinical trials: selecting recruitment rates and trial lengths in different regulatory contexts. Manage Sci. 2023;69(6):3516\u201335.","journal-title":"Manage Sci"},{"key":"2566_CR6","doi-asserted-by":"publisher","unstructured":"Chick S, Gans N, Yapar O. Sequential, value-based designs for certain clinical trials with multiple arms having correlated rewards. In: Winter Simulation Conference (WSC); 2019. 2019. Available from: https:\/\/doi.org\/10.1287\/mnsc.2021.4137","DOI":"10.1287\/mnsc.2021.4137"},{"issue":"5","key":"2566_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/rssb.12225","volume":"79","author":"S Chick","year":"2017","unstructured":"Chick S, Forster M, Pertile P. A Bayesian decision theoretic model of sequential experimentation with delayed response. J R Stat Soc Ser B Stat Methodol. 2017;79(5):1439\u201362.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"7","key":"2566_CR8","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1287\/mnsc.2021.4137","volume":"68","author":"S Chick","year":"2022","unstructured":"Chick S, Gans N, Yapar O. Bayesian sequential learning for clinical trials of multiple correlated medical interventions. Manage Sci. 2022;68(7):4919\u201338.","journal-title":"Manage Sci"},{"issue":"1","key":"2566_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1745-6215-13-168","volume":"13","author":"M Sydes","year":"2012","unstructured":"Sydes M, Parmar M, Mason M, Clarke N, Amos C, Anderson J. Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13(1):168.","journal-title":"Trials"},{"key":"2566_CR10","unstructured":"Nuffield_Department_of_Population_Health. Randomised Evaluation of COVID-19 Therapy RECOVERY trial 2020. Available from: https:\/\/www.recoverytrial.net\/. Cited 2020 Nov 14."},{"key":"2566_CR11","unstructured":"National Instituite of Health Research. Delivering complex and innovative trials 2020. 2020. Available from: https:\/\/www.nihr.ac.uk\/partners-and-industry\/industry\/run-your-study-in-the-nhs\/complex-innovative-trials.htm.\u00a0Cited 2020 Nov 13.\u00a0"},{"key":"2566_CR12","unstructured":"National Institute of Health Research. Annual Efficient Studies funding calls for CTU projects. 2019. Available from: https:\/\/www.nihr.ac.uk\/documents\/ad-hoc-funding-calls-for-ctu-projects\/20141"},{"issue":"1","key":"2566_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13063-016-1273-9","volume":"17","author":"I Hatfield","year":"2016","unstructured":"Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials. 2016;17(1):150.","journal-title":"Trials"},{"key":"2566_CR14","doi-asserted-by":"publisher","unstructured":"Thorlund K, Haggstrom J, Park J, Mills E. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698. https:\/\/doi.org\/10.1136\/bmj.k698.","DOI":"10.1136\/bmj.k698"},{"key":"2566_CR15","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. 2019. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm201790.pdf. Cited 2020 Mar 26."},{"key":"2566_CR16","unstructured":"Committee for Medicinal Products for Human Use, (CHMP) European Medicines Agency. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. 2007. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf"},{"key":"2566_CR17","doi-asserted-by":"crossref","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining Elements of Value in Health Care\u2014A Health Economics Approach: An ISPOR Special Task Force Report [3]. Value Heal. 2018;21(2):131\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301517338925","DOI":"10.1016\/j.jval.2017.12.007"},{"key":"2566_CR18","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. 2022. Available from: https:\/\/www.nice.org.uk\/process\/pmg20\/chapter\/incorporating-economic-evaluation"},{"issue":"6","key":"2566_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1017\/S0266462314000701","volume":"30","author":"S Mohiuddin","year":"2014","unstructured":"Mohiuddin S, Fenwick E, Payne K. Use of value of information in UK health technology assessments. Int J Technol Assess Health Care. 2014;30(6):553.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"2566_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, et al. Value of Information Analysis for Research Decisions\u2014An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value Heal. 2020;23(2):139\u201350.","journal-title":"Value Heal"},{"issue":"3","key":"2566_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","volume":"23","author":"C Rothery","year":"2020","unstructured":"Rothery C, Strong M, Koffijberg HE, Basu A, Ghabri S, Knies S, et al. Value of information analytical methods: report 2 of the ISPOR value of information analysis emerging good practices task force. Value Heal. 2020;23(3):277\u201386.","journal-title":"Value Heal"},{"key":"2566_CR22","doi-asserted-by":"publisher","unstructured":"Ahern A, Woolston J, Wells E, Sharp S, Islam N, Lawlor E, et al. Clinical and cost-effectiveness of a diabetes education and behavioural weight management programme versus a diabetes education programme in adults with a recent diagnosis of type 2 diabetes\u202f: study protocol for the glucose lowering through weight managem. BMJ Open. 2020;10(4):e035020. https:\/\/doi.org\/10.1136\/bmjopen-2019-035020.","DOI":"10.1136\/bmjopen-2019-035020"},{"key":"2566_CR23","doi-asserted-by":"crossref","unstructured":"Pollard D, Brennan A, Coates L, Heller S. PDB65 Pretrial Modelling Methods to Justify and Inform the Design of Large RCTS - Expected Value of Sample Information for the DAFNEPLUS Diabetes Education Cluster RCT. Value Heal. 2019;S584\u2013S584.","DOI":"10.1016\/j.jval.2019.09.947"},{"key":"2566_CR24","doi-asserted-by":"publisher","unstructured":"Flight L, Arshad F, Barnsley R, Patel K, Julious S, Brennan A, et al. A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis. Value Health. 2019;22(4):391\u20138. https:\/\/doi.org\/10.1016\/j.jval.2018.11.008.","DOI":"10.1016\/j.jval.2018.11.008"},{"issue":"1","key":"2566_CR25","first-page":"1","volume":"21","author":"L Flight","year":"2020","unstructured":"Flight L, Julious SA, Brennan A, Todd S, Hind D. How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis Trials. 2020;21(1):1\u201312.","journal-title":"A qualitative analysis Trials"},{"key":"2566_CR26","unstructured":"Wu J, Frazier P. The parallel knowledge gradient method for batch Bayesian optimization. In: Advances in Neural Information Processing Systems. 2016."},{"issue":"1","key":"2566_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/biom.12738","volume":"74","author":"S Villar","year":"2018","unstructured":"Villar S, Rosenberger W. Covariate-adjusted response-adaptive randomization for multi-arm clinical trials using a modified forward looking Gittins index rule. Biometrics. 2018;74(1):49\u201357.","journal-title":"Biometrics"},{"issue":"5","key":"2566_CR28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1287\/opre.49.5.732.10615","volume":"49","author":"S Chick","year":"2001","unstructured":"Chick S, Inoue K. New two-stage and sequential procedures for selecting the best simulated system. Oper Res. 2001;49(5):732\u201343.","journal-title":"Oper Res"},{"key":"2566_CR29","unstructured":"Oakley J, O\u2019Hagan A. School of Mathematics and Statistics, University of Sheffield, UK. 2010. SHELF: the Sheffield elicitation framework (version 2.0)."},{"issue":"2","key":"2566_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ejor.2015.06.077","volume":"248","author":"V Ahuja","year":"2016","unstructured":"Ahuja V, Birge J. Simultaneous learning from multiple patients. Eur J Oper Res. 2016;248(2):619\u201333.","journal-title":"Eur J Oper Res"},{"issue":"1","key":"2566_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1287\/opre.1110.0999","volume":"60","author":"I Ryzhov","year":"2012","unstructured":"Ryzhov I, Powell W, Frazier P. The knowledge gradient algorithm for a general class of online learning problems. Oper Res. 2012;60(1):180\u201395.","journal-title":"Oper Res"},{"key":"2566_CR32","doi-asserted-by":"publisher","unstructured":"Yapar \u00d6, Chick SE, Gans N. Conditional Approval and Value-Based Pricing for New Health Technologies. Manage Sci. 2024 Nov 19; Available from: https:\/\/pubsonline.informs.org\/doi\/https:\/\/doi.org\/10.1287\/mnsc.2022.03628","DOI":"10.1287\/mnsc.2022.03628"},{"key":"2566_CR33","doi-asserted-by":"crossref","unstructured":"Alban A, Chick, Stephen E Zoumpoulis S. Learning Personalized Treatment Strategies with Predictive and Prognostic Covariates in Adaptive Clinical Trials. NSEAD Work Pap No 2022\/33\/TOM\/DSC,. 2024; Available from: https:\/\/ssrn.com\/abstract=4160045","DOI":"10.2139\/ssrn.4160045"},{"key":"2566_CR34","unstructured":"Raiffa H, Schlaifer R. Applied statistical decision theory. 1961."},{"issue":"3","key":"2566_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2307\/2983527","volume":"157","author":"D Spiegelhalter","year":"1994","unstructured":"Spiegelhalter D, Freedman L, Parmar M. Bayesian approaches to randomized trials. J R Stat Soc Ser A Stat Soc. 1994;157(3):357\u201387.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"2566_CR36","unstructured":"U.S. Food and Drug Administration. Draft guidance for industry: Interacting with the FDA on Complex Innovative Trial Designs for drugs and biological products. 2019."},{"issue":"5","key":"2566_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0272989X15575286","volume":"35","author":"M Strong","year":"2015","unstructured":"Strong M, Oakley JE, Brennan A, Breeze P. Estimating the expected value of sample information using the probabilistic sensitivity analysis sample: A fast, nonparametric regression-based method. Med Decis Mak. 2015;35(5):570\u201383.","journal-title":"Med Decis Mak"},{"issue":"4","key":"2566_CR38","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/0272989X07302555","volume":"27","author":"A Brennan","year":"2007","unstructured":"Brennan A, Kharroubi S, O\u2019Hagan A, Chilcott J. Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms. Med Decis Mak. 2007;27(4):448\u201370.","journal-title":"Med Decis Mak"},{"issue":"1","key":"2566_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jhealeco.2006.06.002","volume":"26","author":"A Brennan","year":"2007","unstructured":"Brennan A, Kharroubi S. Efficient computation of partial expected value of sample information using Bayesian approximation. J Health Econ. 2007;26(1):122\u201348.","journal-title":"J Health Econ"},{"key":"2566_CR40","doi-asserted-by":"crossref","unstructured":"Alban A, Chick S, Forster M. Extending a Bayesian decision-theoretic approach to value-based sequential clinical trial design. In: Winter Simulation Conference (WSC); 2018:2018. Available at: https:\/\/www.informs-sim.org\/wsc18papers\/includes\/files\/216.pdf.","DOI":"10.1109\/WSC.2018.8632500"},{"key":"2566_CR41","unstructured":"Powell W, Ryzhov I. Optimal learning. Wiley; 2012. p. 414. ISBN: 978-0-470-59669-2."},{"key":"2566_CR42","unstructured":"DeGroot M. Optimal statistical decisions. Wiley; 2005. p. 512. ISBN: 978-0-471-68029-1."},{"key":"2566_CR43","unstructured":"Forster M, Flight L, Corbacho B, Keding A, Ronaldson S, Tharmanathan P, et al. Report for the EcoNomics of Adaptive Clinical Trials (ENACT) project\u202f: Application of a Bayesian Value-Based Sequential Model of a Clinical Trial to the CACTUS and HERO Case Studies (with Guidance Material for Clinical Trials Units). 2021. Available from: https:\/\/eprints.whiterose.ac.uk\/180084\/"},{"issue":"27","key":"2566_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19270","volume":"19","author":"H Handoll","year":"2015","unstructured":"Handoll H, Brealey S, Rangan A, Keding A, Corbacho B, Jefferson L. The ProFHER (PROximal Fracture of the Humerus: Evaluation by Randomisation) trial-a pragmatic multicentre randomised controlled trial evaluating the clinical effectiveness and cost-effectiveness of surgical compared with non-surgical treatment for proxima. Heal Technol Assess (Winchester, England). 2015;19(27):1.","journal-title":"Heal Technol Assess (Winchester, England)"},{"issue":"7","key":"2566_CR45","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/STROKEAHA.112.650671","volume":"43","author":"R Palmer","year":"2012","unstructured":"Palmer R, Enderby P, Cooper C, Latimer N, Julious S, Paterson G, et al. Computer therapy compared with usual care for people with long-standing aphasia poststroke: A pilot randomized controlled trial. Stroke. 2012;43(7):1904\u201311.","journal-title":"Stroke"},{"issue":"14","key":"2566_CR46","first-page":"64","volume":"14","author":"S Kingsbury","year":"2019","unstructured":"Kingsbury S, Tharmanathan P, Adamson J, Arden N, Birrell F, Cockayne S. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial. Trials. 2019;14(14):64.","journal-title":"Trials"},{"issue":"6","key":"2566_CR47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/17407745211032909","volume":"18","author":"M Forster","year":"2021","unstructured":"Forster M, Brealey S, Chick S, Keding A, Corbacho B, Alban A, et al. Cost-Effective Clinical Trial Design: Application of a Bayesian Sequential Stopping Rule to the ProFHER Pragmatic Trial. Clin Trials. 2021;18(6):647\u201356.","journal-title":"Clin Trials"},{"key":"2566_CR48","doi-asserted-by":"publisher","unstructured":"Welch C, Forster M, Ronaldson S, Keding A, Corbacho-Mart\u00edn B, Tharmanathan P. The performance of a Bayesian value-based sequential clinical trial design in the presence of an equivocal cost-effectiveness signal: evidence from the HERO trial. BMC Med Res Methodol. 2024;24(1):155. Available from: https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12874-024-02248-9","DOI":"10.1186\/s12874-024-02248-9"},{"key":"2566_CR49","doi-asserted-by":"crossref","unstructured":"Flight L, Brennan A, Wilson I, Chick SE. A Tutorial on Value-Based Adaptive Designs: Could a Value-Based Sequential 2-Arm Design Have Created More Health Economic Value for the Big CACTUS Trial? Value Heal. 2024 Oct;27(10):1328\u201337. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524027426","DOI":"10.1016\/j.jval.2024.06.004"},{"issue":"3","key":"2566_CR50","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1302\/0301-620X.99B3.BJJ-2016-1028","volume":"99","author":"H Handoll","year":"2017","unstructured":"Handoll H, Keding A, Corbacho B, Brealey S, Hewitt C, Rangan A. Five-year follow-up results of the PROFHER trial comparing operative and non-operative treatment of adults with a displaced fracture of the proximal humerus. Bone Joint J. 2017;99(3):383\u201392.","journal-title":"Bone Joint J"},{"key":"2566_CR51","unstructured":"National Institute of Health Research. Funding and Awards. 2022. Clinical and cost effectiveness of aphasia computer therapy compared with usual stimulation or attention control long term post stroke (CACTUS). Available from: https:\/\/fundingawards.nihr.ac.uk\/award\/12\/21\/01"},{"key":"2566_CR52","doi-asserted-by":"crossref","unstructured":"Latimer N, Bhadhuri A, Alshreef A. Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation. Clin Rehabil. 2020;","DOI":"10.1177\/0269215520975348"},{"key":"2566_CR53","doi-asserted-by":"publisher","unstructured":"Ronaldson S, Keding A, Tharmanathan P, Arundel C, Kingsbury S, Conaghan P, et al. Cost-effectiveness of hydroxychloroquine versus placebo for hand osteoarthritis: economic evaluation of the HERO trial. F1000Res. 2021;10:821. https:\/\/doi.org\/10.12688\/f1000research.55296.1.","DOI":"10.12688\/f1000research.55296.1"},{"key":"2566_CR54","doi-asserted-by":"crossref","unstructured":"O\u2019Hagan A, Buck C, Daneshkhah A, Eiser J, Garthwaite P, Jenkinson D. Uncertain judgements: eliciting experts\u2019 probabilities. John Wiley & Sons; 2006.","DOI":"10.1002\/0470033312"},{"key":"2566_CR55","unstructured":"Flight L. The use of health economics in the design and analysis of adaptive clinical trials. PhD thesis. University of Sheffield; 2020. Available at: https:\/\/etheses.whiterose.ac.uk\/id\/oai_id\/oai:etheses.whiterose.ac.uk:27924."},{"key":"2566_CR56","unstructured":"Chick SE, Forster M, Pertile P. htadelay package. 2017. Available from: https:\/\/github.com\/sechick\/htadelay"},{"key":"2566_CR57","unstructured":"Flight L. Report to NIHR. Value-based Adaptive Clinical Trial Designs for Efficient Delivery of NIHR Research - EcoNomics of Adaptive Clinical Trials (ENACT) [Internet]. 2021. Available from: https:\/\/www.nihr.ac.uk\/documents\/explore-nihr\/Efficient studies\/Sheffield CTRU ENACT - NIHR Final Report 31March2021.docx#:~:text=The EcoNomics of Adaptive Clinical,and weaknesses by assessing its"},{"key":"2566_CR58","unstructured":"NHS England. 12 Actions to support and apply research in the NHS 2017. 2017. Available from: https:\/\/www.england.nhs.uk\/publication\/12-actions-to-support-and-apply-research-in-the-nhs\/."},{"key":"2566_CR59","unstructured":"Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z. A pilot study of value of information analysis to support research recommendations for NICE. 2017."},{"key":"2566_CR60","doi-asserted-by":"publisher","unstructured":"Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P. The role of modelling in prioritising and planning clinical trials. Health Technol Assess. 2003;7(23):iii, 1\u2013125. https:\/\/doi.org\/10.3310\/hta7230.","DOI":"10.3310\/hta7230"},{"key":"2566_CR61","doi-asserted-by":"crossref","unstructured":"Claxton K, Sculpher M. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24(11):1055\u201368. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17067191","DOI":"10.2165\/00019053-200624110-00003"},{"key":"2566_CR62","doi-asserted-by":"publisher","unstructured":"Woods B, Schmitt L, Rothery C, Phillips A, Hallett T, Revill P. Practical metrics for establishing the health benefits of research to support research prioritisation. BMJ Glob Health. 2020;5(8):e002152. https:\/\/doi.org\/10.1136\/bmjgh-2019-002152.","DOI":"10.1136\/bmjgh-2019-002152"},{"issue":"10","key":"2566_CR63","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/hec.1797","volume":"21","author":"N Welton","year":"2012","unstructured":"Welton N, Ades A. Research decisions in the face of heterogeneity: what can a new study tell us? Health Econ. 2012;21(10):1196\u2013200.","journal-title":"Health Econ"},{"key":"2566_CR64","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","volume":"64","author":"SJ Pocock","year":"1977","unstructured":"Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64:191\u20139.","journal-title":"Biometrika"},{"key":"2566_CR65","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2307\/2530245","volume":"35","author":"PC O\u2019Brien","year":"1979","unstructured":"O\u2019Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549\u201356.","journal-title":"Biometrics"},{"key":"2566_CR66","volume-title":"DB R","author":"A Gelman","year":"2013","unstructured":"Gelman A, Carlin J, Stern H, Dunson D, Vehtari A. DB R. Bayesian data analysis: CRC Press; 2013."},{"key":"2566_CR67","first-page":"369","volume":"17","author":"M Dimairo","year":"2020","unstructured":"Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, et al. The Adaptive designs CONSORT Extension (ACE) Statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ. 2020;17:369.","journal-title":"BMJ"},{"key":"2566_CR68","doi-asserted-by":"publisher","unstructured":"Lamont T, Barber N, de Pury J, Fulop N, Garfield-Birkbeck S, Lilford R, Mear L, Raine R, Fitzpatrick R. New approaches to evaluating complex health and care systems. BMJ (Clinical research ed). 2016;352:i154. https:\/\/doi.org\/10.1136\/bmj.i154.","DOI":"10.1136\/bmj.i154"},{"key":"2566_CR69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41416-019-0653-9","volume":"122","author":"SP Blagden","year":"2020","unstructured":"Blagden SP, Billingham L, Brown LC, Buckland SW, Cooper AM, Ellis S, et al. Effective delivery of Complex Innovative Design (CID) cancer trials\u2014A consensus statement. Br J Cancer. 2020;122:473\u201382.","journal-title":"Br J Cancer"},{"issue":"2","key":"2566_CR70","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1740774512474375","volume":"10","author":"T Jaki","year":"2013","unstructured":"Jaki T. Uptake of novel statistical methods for early-phase clinical studies in the UK public sector. Clin Trials. 2013;10(2):344\u20136.","journal-title":"Clin Trials"},{"issue":"1","key":"2566_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-015-0958-9","volume":"16","author":"M Dimairo","year":"2015","unstructured":"Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S. Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials. 2015;16(1):1\u201316.","journal-title":"Trials"},{"issue":"11","key":"2566_CR72","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/sim.8086","volume":"38","author":"TP Morris","year":"2019","unstructured":"Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods. Stat Med. 2019;38(11):2074\u2013102.","journal-title":"Stat Med"},{"key":"2566_CR73","unstructured":"NIHR\/NETSCC. The Clinical Trials Toolkit - Routemap 2020. 2020. The Clinical Trials Toolkit - Routemap 2020. Available from: https:\/\/www.ct-toolkit.ac.uk\/routemap\/dissemination-of-results\/downloads\/ct-toolkit-v1.1.pdf.\u00a0Cited 2020 Nov 14."}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02566-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-025-02566-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02566-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:10:03Z","timestamp":1749107403000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-025-02566-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2566"],"URL":"https:\/\/doi.org\/10.1186\/s12874-025-02566-6","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the secondary use of the HERO data was granted by the ScHARR research ethics committee (ref: 032229).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PT is part funded by the NIHR Research Support Service. He is a co-applicant on a number of NIHR research grants. LF and PT were part funded by the now defunct NIHR Research Design Service when participating in the ENACT stakeholder events. AB, MF, SC, SAJ have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}